Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

doi:10.1007/s11684-023-1046-2

2024, Vol. 18

Issue (3) : 565-569 https://doi.org/10.1007/s11684-023-1046-2

Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

Jia Jia¹, Lili Mao², Jing Lin³, Wenyu Li², Pei Yuan¹, Lei Guo¹, Jie Dai², Caili Li², Xue Bai², Zhongwu Li⁴, Yu Chen³, Jun Guo², Jianming Ying¹(

), Lu Si²(

)

¹. State Key Laboratory of Molecular Oncology, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
². Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing 100142, China
³. Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China
⁴. Department of Pathology, Peking University Cancer Hospital & Institute, Beijing 100142, China

Download: PDF(949 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Corresponding Author(s): Jianming Ying,Lu Si

Just Accepted Date: 12 April 2024 Online First Date: 13 May 2024 Issue Date: 17 June 2024

Cite this article:

Jia Jia,Lili Mao,Jing Lin, et al. Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy[J]. Front. Med., 2024, 18(3): 565-569.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-023-1046-2
https://academic.hep.com.cn/fmd/EN/Y2024/V18/I3/565

Fig.1 HER2 status in extramammary Paget disease and efficiency of disitamab vedotin. (A) Distribution of HER2 status based on IHC. (B) Association between HER2 status and clinicopathological features of EMPD. (C) Correlation between HER2 expression and gene amplification. (D, E) Compared with deeply invasive EMPD, intraepithelial and superficially invasive tumors had similar OS and DFS rates. (F, G) Stratification of survival based on the lymph node (LN) status in the entire cohort, revealing distinct survival patterns. (H, I) Patients with a HER2 score of 2+ and 3+ tended to have worse survival than those with 1+/0 in the invasive EMPD cohort. Case 1 (J–L) and case 2 (M–O) received DV therapy: (J) IHC of the right inguinal lymph node metastasis showing a HER2 score of 2+ (200×); pre-treatment-enhanced CT shows multiple lesions at the groin and perineum area (K); after 8 weeks of treatment, the patient had PR at CT evaluation (L); (M) IHC of the left cervical lymph node metastasis with a HER2 score of 1+ (200×); (N) PET scan performed on the 12th of July 2022 showed multiple lymph nodes with FDG accumulation: bilateral cervical, supraclavicular, hilar, and other lymph nodes; (O) PET scan performed on September 29, 2022, showed significant shrinking of patients’ tumors.

1	SH Jeong, JH Hyeong, EJ Park, KJ Kim, KH Kim. Human epidermal growth factor receptor 2 expression in extramammary Paget’s disease and mammary Paget’s disease. Australas J Dermatol 2022; 63(1): 115–118 https://doi.org/10.1111/ajd.13782
2	G Angelico, A Santoro, F Inzani, P Straccia, D Arciuolo, A Mulè, M Valente, S Spadola, N D’Alessandris, G Garganese, F Cianfrini, A Piermattei, G Scambia, GF Zannoni. Hormonal environment and HER2 status in extra-mammary Paget’s disease (eMPD): a systematic literature review and meta-analysis with clinical considerations. Diagnostics (Basel) 2020; 10(12): 1040 https://doi.org/10.3390/diagnostics10121040
3	N Sekiguchi, S Kubota, T Noguchi, T Fukushima, T Kobayashi, S Kanda, T Koizumi, T Miyake, T Shirai, R Okuyama. Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget’s disease: four cases and a review. J Dermatol 2020; 47(11): 1276–1279 https://doi.org/10.1111/1346-8138.15515
4	National Medical Products Administration. Disitamab vedotin: NMPA Approval notice. 2021, available from the website of NMPA
5	RemeGen. Disitamab vedotin: Chinese prescribing information. Yantai. 2021
6	J Wang, Y Liu, Q Zhang, J Feng, J Fang, X Chen, Y Han, Q Li, P Zhang, P Yuan, F Ma, Y Luo, Y Fan, R Cai, S Chen, Q Li, Y Li, B Xu. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. J Clin Oncol 2021; 39(15 Suppl): 1022 (abstract no. 1022) https://doi.org/10.1200/JCO.2021.39.15_suppl.1022
7	Y Xu, Y Wang, J Gong, X Zhang, Z Peng, X Sheng, C Mao, Q Fan, Y Bai, Y Ba, D Jiang, F Yang, C Qi, J Li, X Wang, J Zhou, M Lu, Y Cao, J Yuan, D Liu, Z Wang, J Fang, L Shen. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 2021; 24(4): 913–925 https://doi.org/10.1007/s10120-021-01168-7
8	E Zattarin, F Nichetti, F Ligorio, L Mazzeo, R Lobefaro, G Fucà, G Peverelli, A Vingiani, GV Bianchi, G Capri, Braud F de, C Vernieri. Case Report: prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin. Front Oncol 2022; 12: 925551 https://doi.org/10.3389/fonc.2022.925551
9	DS Shin, T Sherry, ME Kallen, S Wong, A Drakaki. Human epidermal growth factor receptor 2 (HER-2/neu)-directed therapy for rare metastatic epithelial tumors with HER-2 amplification. Case Rep Oncol 2016; 9(2): 298–304 https://doi.org/10.1159/000445827
10	K Tokuchi, T Maeda, S Kitamura, T Yanagi, H Ujiie. HER2-targeted antibody-drug conjugates display potent antitumor activities in preclinical extramammary Paget’s disease models: in vivo and immunohistochemical analyses. Cancers (Basel) 2022; 14(14): 3519 https://doi.org/10.3390/cancers14143519

[1]

FMD-23065-OF-SL_suppl_1

Download

Viewed

Full text

Abstract

Cited

Shared

Discussed